Home > Healthcare > Pharmaceuticals > Drug Delivery > Nicotine Replacement Therapy Market

Nicotine Replacement Therapy Market Share

Report ID: GMI7725
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Nicotine Replacement Therapy Market Share

The market is characterized by diverse players competing in the industry. These prominent players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion, innovative product launches, marketing and advertisement, and regulatory compliance to provide comprehensive range of products and maintain a competitive edge in the market.

Nicotine Replacement Therapy Market Companies

Foremost players operating in the nicotine replacement therapy industry is as mentioned below:

Pfizer, Inc.
Glenmark Pharmaceuticals Limited
Johnson & Johnson
Cipla Ltd.
Fertin Pharma
Rubicon Research Pvt Ltd.
Sparsh Pharma
GlaxoSmithKline plc
Perrigo Company plc
Pierre Fabre Group

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Nicotine replacement therapy industry size was USD 3.1 billion in 2023 and is estimated to reach USD 6.2 billion by 2032 due to the increasing cases of cancer globally, rising smoking cessation initiatives, and the growing health awareness & education

The gums product type segment held 49.7% share of the market in 2023 owing to their ability to manage withdrawal symptoms in a controlled manner.

The oral route of administration segment recorded USD 2.3 billion in revenue in 2023 and will foresee significant expansion between 2024 and 2032 as they are easy to use, allowing individuals to manage cravings in various situations.

North America held 48.4% of the global nicotine replacement therapy market share in 2023 owing to the strong awareness of the health risks associated with smoking in the region